AbbVie Boosts FY24 Outlook - Update

RTTNews | 95 दिनों पहले
Stocktwits
AbbVie Boosts FY24 Outlook - Update

(RTTNews) - While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2024.

For fiscal 2024, AbbVie now projects adjusted earnings in a range of $10.71 to $10.91 per share, which includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2024.

However, the adjusted earnings guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted.

Previously, the company expected adjusted earnings in the range of $10.61 to $10.81 per share.

On average, 20 analysts polled by Thomson Reuters expect the company to report earnings of $9.93 per share for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

टैग: ABBV
Stocktwits
read more
AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis

AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis

AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ 15 mg, once daily) for the treatment of adult patients with giant cell arteritis (GCA).
RTTNews | 108 दिनों पहले
AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients

AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients

AbbVie, Inc. (ABBV) announced Tuesday that a new weight-based oral solution RINVOQ LQ (upadacitinib) is now available as an option for pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
RTTNews | 146 दिनों पहले
AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO

AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO

AbbVie, Inc. (ABBV) announced Tuesday that its board of directors has unanimously selected Robert Michael, AbbVie's current president and chief operating officer, to succeed Richard Gonzalez as the company's chief executive officer.
RTTNews | 251 दिनों पहले
AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln

AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln

AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
RTTNews | 333 दिनों पहले
AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin

AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin

Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The trial demonstrated compelling clinical benefits across key endpoints.
RTTNews | 334 दिनों पहले
AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint

AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint

AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.
RTTNews | 395 दिनों पहले
AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab

AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab

Biopharmaceutical company AbbVie, Inc. (ABBV) announced Tuesday top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg subcutaneous injection [SC] starting at week 12 and every 8 weeks thereafter) versus ustekinumab (STELARA, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) through week 48 in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.
RTTNews | 412 दिनों पहले
उपकरण
आर्थिक कैलेंडर
Market Hours
Interest Rates
Holidays Calendar
फोरेक्स मार्केट
फोरेक्स वॉलटीलिटी (अस्थिरता)
फोरेक्स कोरीलैशन
फोरेक्स के समाचार
forex analysis
सीओटी डाटा
लिक्विडिटी
फॉरेक्स कैल्कुलेटर
फोरेक्स के हीट का नक्शा
Indicators Heatmap
कम्युनिटी
कम्युनिटी
सिस्टमों
सर्व प्रसिद्ध सिस्टमों
रणनीतियां
प्रतियोगिता
फोरेक्स चार्टों
फोरेक्स भावना
आउटलुक इंडिकेटर
रीव्यूज़
ब्रोकरों
Prop Trading Firms
वी पी एस की सेवाएं
सिगनल को उपलब्ध कराने वाले
EA प्रोग्रामिंग की सेवाएं
Affiliate Programs
PAMM ब्रोकर की सेवाएं
रीबैट कार्यक्रम की सेवाएं
ट्रेडिंग के प्लैटफॉर्म
माहिर सलाहकारों
क्रिप्टो एक्सचेंज
Trading Courses
ब्रोकरों
फोरेक्स स्प्रेड
फोरेक्स ब्रोकर के क्वोट-चिह्न.
फोरेक्स ब्रोकरों के स्वाप
फोरेक्स ब्रोकर वॉल्यूम
फोरेक्स ब्रोकर की पदोन्नति Broker News
प्लेटफॉर्म
विजेट
विशेषताएं
API
RSS
Stock Portfolio
Affiliate Software
एडवांस चार्ट
सहयोग
अधिकतम पूछे जाने वाले प्रश्न (एफएक्यू )
सहायता
हमसे संपर्क करें
बग को रिपोर्ट करें!
बारे में
ब्लॉग
&प्रतिलिपि; 2024 Myfxbook Ltd. सर्वाधिकार सुरक्षित.
उच्च जोखिम चेतावनी: फॉरन एक्सचेंज ट्रेडिंग में उच्च स्तर का खतरा होता है जो हर निवेशकों के लिए सही नहीं हो सकता. लीवरेज अधिकतम खातर और हानि के अनावरण को उत्पन्न करता है. इससे पहले कि आप निर्णय लें फॉरन एक्सचेंज में ट्रेड करने का, ध्यान अपने निवेश के उद्देश्यों, अनुभव स्तर, और खतरा उठाने की सहिष्णुता पर विचार करें. आप कुछ या अपनी प्रारंभिक निवेश को खो सकते हैं. बिल्कुल भी उस पैसे को निवेश ना करें जो आप खोने को बर्दाश्त नहीं कर सकते. अपने आप को शिक्षित करें उन खतरों से जो फॉरन एक्सचेंज ट्रेडिंग से संबंधित हैं, और सलाह लें किसी स्वतंत्र आर्थिक या कर सलाहकार से अगर आपके पास कोई भी प्रश्न हैं तो. कोई भी डाटा या जानकारों जो दी जाती है वे केवल सूचनात्मक उद्देश्यों के लिए है, और यब ट्रेडिंग आशय या सलाह पर नियत नहीं है. पिछले निष्पादन भविष्य के परिणामों के लिए परियाचक नहीं हैं.